Table 1 Characteristics of the 80 BM patients analyzed
From: Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?
Characteristics | No./median (range) | % |
|---|---|---|
Sex (m/f) | 49/31 | 61,3% / 38,8% |
Age (y) | 61 (16.2 - 88.7) | |
KPS | ||
100 | 20 | 25.0% |
90 | 25 | 31.3% |
80 | 17 | 21.3% |
70 | 7 | 8.8% |
60 | 4 | 5.0% |
50 | 1 | 1.3% |
n/a | 6 | 7.5% |
Histology | ||
SSM | 10 | 12.5% |
NM | 22 | 27.5% |
LMM | 2 | 2.5% |
ALM | 2 | 2.5% |
AMM | 3 | 3.8% |
occult | 13 | 16.3% |
n/a | 28 | 35.0% |
UICC stage at diagnosis | ||
I-III | 60 | 75.0% |
IV | 20 | 25.0% |
Synchronous BM | 4 | 5.0% |
Number of treated lesions | ||
1 | 35 | 43.8% |
2 | 24 | 30.0% |
> = 3 | 21 | 26.3% |
Cumulative lesion volume (ccm) | 2.47 (0.02-41.68) | |
BED10 | 91.1 (39-91.1) | |
Fractionation | ||
SRS | 59 | 73.8% |
FSRT | 7 | 8.8% |
Both | 14 | 17.5% |
Salvage WBRT | 8 | 10.0% |
Salvage SRT | 23 | 28.8% |
Salvage Resection | 1 | 1.3% |
Targeted therapya | ||
Vemurafinib | 2 | 2.5% |
Ipilimumab | 4 | 5.0% |
Dabrafenib | 1 | 1.3% |